Picture of Immuron logo

IMC — Immuron News Story

0.000.00%
au flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapNeutral

Immuron surges as FDA lifts hold on diarrhoea drug trial

** U.S.-listed shares of Australia's Immuron Ltd  IMRN.O 
surge 72.7% to $3.23 premarket
    ** Co  IMC.AX  says FDA removes clinical hold, allowing the
U.S. Naval Medical Research Center to evaluate efficacy of
diarrhoea drug, Travelan 
    ** Travelan, co-developed with Immuron, is an oral
immunotherapeutic drug to treat gut-mediated diseases caused by
various types of bacteria
    ** Drug's safety and efficacy will be tested in two trials,
with one focusing on the drug's ability against ETEC infections
and the focusing on moderate to severe campylobacteriosis
    ** As of last close, stock down ~15% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))

Recent news on Immuron

See all news